Magellan BioScience Group, Inc.
6101 Johns Road, Suite 8,
Tampa, FL 33634 USA
Tel (727) 865-1300
Fax (813) 514-9401
Deborah Robison
Director of Communications
Burnham Institute for Medical Research
at Lake Nona
6400 Sanger Road
Orlando, FL 32827
Phone(407) 745- 2073
Email: Drobison@Burnham.org
Burnham Institute for Medical Research and Magellan BioScience Group, Inc. Announce Drug Discovery
Collaboration
Tampa and Orlando, FL (06 July 2009) – Magellan BioScience Group, Inc. (Magellan), a pioneer in innovative drug
development from marine sources, and investigators at the Burnham Institute for Medical Research at Lake Nona
(Burnham) announced today that they will begin a multidisciplinary drug discovery collaboration to identify novel
marine microbial compounds that have potential as tools for biological research and ultimately the discovery of new
medicines.
This collaboration will bring together Magellan’s unique collection of marine-derived microorganisms and their
natural product chemistry expertise with Burnham’s ultra-high throughput small molecule screening technologies
that were recently established at the Lake Nona, Florida campus. The Burnham-Magellan team will utilize
Burnham’s state-of-the-art robotic screening system to run bioassays and characterize lead candidates from the
collection. The Burnham team of Medicinal Chemists will then optimize novel compounds to afford potential
biological probes and preclinical drug candidates. The groups’ combined expertise in sophisticated chemistry
approaches and access to advanced screening technologies, will accelerate early discovery and drug development
efforts.
.
“Burnham’s scientific and technological approach coupled with their highly-qualified and industry-experienced
research teams constitutes a significant opportunity for the discovery and development of new pharmaceutical
candidates.”
Burnham’s ultra-high throughput screening resource resides within the Conrad Prebys Center for Chemical
Genomics and is one of four NIH sponsored comprehensive screening and probe development centers in the
United States. The fully-integrated automated system combines robotic screening with high-content image
analysis, hit-to-probe chemistry, exploratory pharmacology expertise, and informatics, provides a technology
platform that is virtually unprecedented in the not-for-profit research world.
“The Burnham-Magellan collaboration will involve some of the first assays to be processed through our new small
molecule screening center at Lake Nona. This is a powerful partnership that will advance both science and regional
development and is representative of the collaborations that were envisioned by Burnham as we established an
east coast campus in Florida,” said Dr. Gregory Roth, associate professor and director of medicinal chemistry and
pharmacology at Burnham.
About Magellan:
Magellan BioScience Group, Inc., based in Tampa, Fla., is a privately held innovative biotechnology company
focused on the discovery of novel classes of therapeutic candidates. Magellan is using its integrated platform
technologies to isolate and identify new biologically active compounds. The company believes that its library of
marine microbes will be the next source of drug discovery for the pharmaceutical industry. Magellan aims to
develop and optimize drug candidates to treat cancer, infectious diseases, and inflammation. For additional
information, please refer to the company’s web site at www.magellanbioscience.com.
About Burnham Institute for Medical Research
Burnham Institute for Medical Research is dedicated to revealing the fundamental molecular causes of disease and
devising the innovative therapies of tomorrow. Burnham, with operations in California and Florida, is one of the
fastest-growing research institutes in the country. The Institute ranks among the top-four institutions nationally for
NIH grant funding and among the top-25 organizations worldwide for its research impact. Burnham utilizes a
unique, collaborative approach to medical research and has established major research programs in cancer,
neurodegeneration, diabetes, infectious and inflammatory and childhood diseases. The Institute is known for its
world-class capabilities in stem cell research and drug discovery technologies. Burnham is a nonprofit, public
benefit corporation. For more information, please visit www.burnham.org.
CONTACTS:
John Michael Cronan, Ph.D.,
Magellan BioScience Group, Inc.
6101 Johns Road, Suite 8
Tampa, FL 33634 USA
Phone: (727) 865-1300
Fax: (813) 514-9401
Email: info@magellanbioscience.com
Dr. Gregory Roth, Ph.D.
Burnham Institute for Medical Research at Lake Nona
6400 Sanger Road
Orlando, FL 32827
Phone(407) 745- 2062
Email: GRoth@Burnham.org
Comentarios